

## ASX ANNOUNCEMENT

### Completion of AUD \$31.5 million Private Placement

**Sydney, Australia, April 15, 2014** - Benitec Biopharma Limited (ASX: BLT), announces that it has successfully completed the private placement of AUD \$31.5 million via institutional investors.

Benitec's shareholders voted overwhelmingly in favour of ratifying the first tranche and approving the second tranche of the private placement at a General Meeting on 10 April 2014. Benitec has now received AUD \$31.5 million which will be used to accelerate clinical development of its lead compound TT-034, a potential "single shot" treatment for hepatitis C. Funds will also be used to advance other programs in the Company's pipeline, with a particular emphasis on the lung cancer, age-related macular degeneration, and hepatitis B programs.

The placement was managed by Maxim Group LLC in the U.S. and Lodge Corporate Pty Ltd in Australia with participation from international institutional investors.

Peter French, Benitec Biopharma's CEO and Managing Director, stated, "We are very pleased to have had the strong support of our shareholders to secure the full amount of the funding. We are now sufficiently resourced to advance all of our programs with the aim of delivering maximum shareholder value. Furthermore, securing new institutional investors from the United States demonstrates confidence in our ddRNAi technology, our pipeline, and in our potential for future growth and value creation."

For further information, please contact the persons below, or visit the Benitec website at [www.benitec.com](http://www.benitec.com).

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: <a href="mailto:cstubbings@benitec.com">cstubbings@benitec.com</a>	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: <a href="mailto:jlowe@buchanwe.com.au">jlowe@buchanwe.com.au</a>

#### **About Benitec Biopharma Limited:**

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com).